Chinese Medicine Treat for Hypertensive Renal Injury (CHAIR)
Primary Purpose
Hypertension, Renal Injury
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Losartan 100Mg Tab
Qianyangyuyin 20g Granule
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Hypertension focused on measuring hypertension, chronic kidney disease, traditional chinese medicine, early renal injury, albumin to creatinine ratio(UACR)
Eligibility Criteria
Inclusion Criteria:
- Subject has primary hypertension(grades 2-3)
- Subject has microalbuminuria [defined as a urinary albumin/creatinine ratio (UACR) between 30 and 300mg/g, and a eGFR at least 60ml/(min∙1.73m2)]
- Subject has ascendant hyperactivity of liver Yang or Yin deficiency in TCM syndrome
- Subject voluntarily participates in the trial and signs informed consent
Exclusion Criteria:
- Subject has secondary hypertension
- Subject with pregnancy or lactating
- Subject has serious life-threatening diseases, such as acute myocardial infarction, stroke, heart failure (NYHA IV), and malignant arrhythmia
- Subject's liver function (AST or ALT) is 2 times greater than normal value
- Subject has history of mental illness
- Subject currently participates in other drug clinical trials
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
losartan & qianyangyuyin
Losartan & Placebo
Arm Description
Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
Outcomes
Primary Outcome Measures
albumin-to-creatinine ratio(UACR)
UACR tested at baseline and each month. Microalbuminuria was defined as urinary ACR of at least 30mg/g.
Secondary Outcome Measures
Ambulatory blood pressure level
ABPM was measured at baseline, 3 and 6 months. Both systolic and diastolic pressure was assessed. Hypertension was defined as mean ambulatory blood pressure of at least 130/80 mmHg.
Office blood pressure level 6/5000 Office blood pressure level
Office blood pressure was measured at baseline and each month. Both systolic and diastolic pressure was assessed. Hypertension was defined as office blood pressure of at least 140/90 mmHg.
Traditional Chinese Medicine syndrome scores
Self reported TCM syndrome scores at baseline and each month. Each main symptom is scored 0、2、4、6 (0 = no sympton; 6 = as heavy as can be), and each secondary symptom is scored 0、1、2、3(0=no symptom; 3= as heavy as can be).
Full Information
NCT ID
NCT04078711
First Posted
September 2, 2019
Last Updated
September 4, 2019
Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Collaborators
Ministry of Science and Technology of the People´s Republic of China, First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
1. Study Identification
Unique Protocol Identification Number
NCT04078711
Brief Title
Chinese Medicine Treat for Hypertensive Renal Injury
Acronym
CHAIR
Official Title
Qianyangyuyin Formula Prevent and Treat for Early Renal Injury in Hypertensive Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 10, 2019 (Anticipated)
Primary Completion Date
June 30, 2021 (Anticipated)
Study Completion Date
December 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine
Collaborators
Ministry of Science and Technology of the People´s Republic of China, First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study evaluates whether the traditional chinese medicine (Qianyangyuyin formula) could prevent and treat early renal injury in patients with hypertension and microalbuminuria (defined as a urinary albumin to creatinine ratio between 30 and 300 mg/g) based on standard antihypertensive treatment.
Detailed Description
Hypertension is the main cardiovascular disease and the most important risk factor for severe lethal and disabling diseases such as stroke, myocardial infarction, heart failure, and chronic renal insufficiency. The higher the blood pressure level, the higher the risk of these diseases. Antihypertensive drugs can control blood pressure, and effectively reduce the risk of these serious complications. A multi-center, randomized, parallel, placebo-controlled clinical study was designed to explore the effectiveness and safety of early intervention of Chinese medicine (Qianyanguuyin formula) in improving urinary albumin to creatinine ratio (ACR), based on standard antihypertensive treatment (losartan 100mg qd, if necessary combined with calcium channel blockers). Patients were recruited if they were (1) age between 35 and 55 years old, (2) primary hypertension (grades 2-3 ), (3) microalbuminuria (ACR of 30-300 mg/g) and eGFR of at least 60 ml / (min∙1.73m2), (4) ascendant hyperactivity of liver Yang or Yin deficiency in TCM syndrome. It's intented to form a standardized plan for the prevention and treatment of early renal injury in hypertensive patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Renal Injury
Keywords
hypertension, chronic kidney disease, traditional chinese medicine, early renal injury, albumin to creatinine ratio(UACR)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
520 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
losartan & qianyangyuyin
Arm Type
Experimental
Arm Description
Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
Arm Title
Losartan & Placebo
Arm Type
Placebo Comparator
Arm Description
Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
Intervention Type
Drug
Intervention Name(s)
Losartan 100Mg Tab
Other Intervention Name(s)
Cozaar
Intervention Description
100Mg Tab, qd, po, 6 months
Intervention Type
Drug
Intervention Name(s)
Qianyangyuyin 20g Granule
Intervention Description
20g, Granule, bid, po, 6 months
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
placebo(qianyangyuyin)
Intervention Description
Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
Primary Outcome Measure Information:
Title
albumin-to-creatinine ratio(UACR)
Description
UACR tested at baseline and each month. Microalbuminuria was defined as urinary ACR of at least 30mg/g.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Ambulatory blood pressure level
Description
ABPM was measured at baseline, 3 and 6 months. Both systolic and diastolic pressure was assessed. Hypertension was defined as mean ambulatory blood pressure of at least 130/80 mmHg.
Time Frame
6 months
Title
Office blood pressure level 6/5000 Office blood pressure level
Description
Office blood pressure was measured at baseline and each month. Both systolic and diastolic pressure was assessed. Hypertension was defined as office blood pressure of at least 140/90 mmHg.
Time Frame
6 months
Title
Traditional Chinese Medicine syndrome scores
Description
Self reported TCM syndrome scores at baseline and each month. Each main symptom is scored 0、2、4、6 (0 = no sympton; 6 = as heavy as can be), and each secondary symptom is scored 0、1、2、3(0=no symptom; 3= as heavy as can be).
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject has primary hypertension(grades 2-3)
Subject has microalbuminuria [defined as a urinary albumin/creatinine ratio (UACR) between 30 and 300mg/g, and a eGFR at least 60ml/(min∙1.73m2)]
Subject has ascendant hyperactivity of liver Yang or Yin deficiency in TCM syndrome
Subject voluntarily participates in the trial and signs informed consent
Exclusion Criteria:
Subject has secondary hypertension
Subject with pregnancy or lactating
Subject has serious life-threatening diseases, such as acute myocardial infarction, stroke, heart failure (NYHA IV), and malignant arrhythmia
Subject's liver function (AST or ALT) is 2 times greater than normal value
Subject has history of mental illness
Subject currently participates in other drug clinical trials
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ming Liu
Phone
13815885859
Email
liumingxinghua@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhuyuan Fang
Organizational Affiliation
Jiangsu Province Hospital of Traditional Chinese Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ming Liu
Organizational Affiliation
Jiangsu Province Hospital of Traditional Chinese Medicine
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
19474763
Citation
Gaziano TA, Bitton A, Anand S, Weinstein MC; International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens. 2009 Jul;27(7):1472-7. doi: 10.1097/HJH.0b013e32832a9ba3.
Results Reference
background
PubMed Identifier
22386035
Citation
Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012 Mar 3;379(9818):815-22. doi: 10.1016/S0140-6736(12)60033-6. Erratum In: Lancet. 2012 Aug 18;380(9842):650.
Results Reference
background
PubMed Identifier
23817082
Citation
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.
Results Reference
background
PubMed Identifier
24352797
Citation
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. Erratum In: JAMA. 2014 May 7;311(17):1809.
Results Reference
background
PubMed Identifier
17984482
Citation
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 Jan 1;148(1):30-48. doi: 10.7326/0003-4819-148-1-200801010-00190. Epub 2007 Nov 5.
Results Reference
background
PubMed Identifier
21388309
Citation
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.
Results Reference
background
PubMed Identifier
21243736
Citation
Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011 Feb;29(2):207-16. doi: 10.1097/hjh.0b013e32834069bd.
Results Reference
background
PubMed Identifier
23747768
Citation
Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R; Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013 Sep 17;62(12):1065-1072. doi: 10.1016/j.jacc.2013.05.035. Epub 2013 Jun 7.
Results Reference
background
PubMed Identifier
11904577
Citation
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. No abstract available.
Results Reference
background
PubMed Identifier
31080465
Citation
Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019 Mar;16(3):182-241. doi: 10.11909/j.issn.1671-5411.2019.03.014. No abstract available.
Results Reference
background
PubMed Identifier
17416265
Citation
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007 Apr 7;369(9568):1208-19. doi: 10.1016/S0140-6736(07)60242-6.
Results Reference
background
Learn more about this trial
Chinese Medicine Treat for Hypertensive Renal Injury
We'll reach out to this number within 24 hrs